Trade Alzamend Neuro, Inc. - ALZN CFD

Trading Conditions

• Spread: 0.0063
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.01
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 0.7047
• Open: 0.7191
• 1-Year Change: 20.37%
• Day's Range: 0.6991 - 0.7191

Alzamend Neuro, Inc. Company profile

About Alzamend Neuro Inc

Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company focused on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The Company's pipeline consists of two therapeutic drug candidates: AL001 and AL002. The AL001 is a cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing worldwide licenses from the University of South Florida Research Foundation, Inc. (licensor). AL002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing worldwide license from the licensor.

Financial summary

BRIEF: For the nine months ended 31 January 2022, Alzamend Neuro Inc revenues was not reported. Net loss increased from $3.8M to $8.5M. Higher net loss reflects Research and development - Bal increase from $953K to $3.2M (expense), Stock-based Compensation in SGA increase of 67% to $2.8M (expense), General and administrative - Bal increase from $547K to $1.1M (expense).